trial

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCTId NCT00772005
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 287 (actual)
Sponsored by Cephalon
Primary completion 2010-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
287 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-09
Primary completion
2010-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
armodafinil

Sponsors

CephalonLead Sponsor

Sites

39 total
Little Rock, United StatesAnaheim, United StatesEscondido, United StatesGarden Grove, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesSanta Ana, United StatesTorrance, United StatesNew Britain, United StatesNew Haven, United StatesAventura, United States

Linked catalysts

1
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy i — primary completion2010-03

Facts & assertions

4 sourced
Enrollment
287
Phase
PHASE2
Primary Completion Date
2010-03
Status
COMPLETED
relationships
The graph out of here
drug
armodafinil
drug
lead_sponsor
Cephalon
company
indication
Schizophrenia
indication
Schizophrenia
indication